Telaprevir's Hidden Talents: New Data Show Effectiveness In Difficult To Cure Populations
This article was originally published in The Pink Sheet Daily
Executive Summary
Treatment-naïve African Americans, Hispanics and patients with liver scarring all had surprisingly better results when the direct-acting antiviral was added to their regimen, Vertex reports.
You may also be interested in...
Boceprevir Hep C Response-Guided Therapy Works For Experienced Patients
About half of experienced patients made enough progress to get into the shortened therapy group, and among them the cure rate was 86%.
Boceprevir Hep C Response-Guided Therapy Works For Experienced Patients
About half of experienced patients made enough progress to get into the shortened therapy group, and among them the cure rate was 86%.
Third Telaprevir Pivotal Study Raises Bar For Competitors Another Notch
Collective top-line data from the Phase III program testing Vertex Pharmaceuticals' protease inhibitor telaprevir in treatment-naïve and treatment-experienced hepatitis C patients set a high bar for competitors, particularly for Merck & Co.'s boceprevir, with which telaprevir is dueling to be the first approved specifically targeted antiviral therapy for hepatitis C (STAT-C).